Scott Brantley, BS

Scott is evaluating a novel in vitro-in silico-in vivo approach to identify potential clinically relevant interactions between drugs and herbal supplements, the latter of which are typically mixtures of multiple, often unknown, bioactive ingredients. Using milk thistle as a model herbal supplement, he is applying this translational research method to predict the likelihood and magnitude of interactions between milk-thistle products and the clinically relevant cytochrome P450 "probe" substrates warfarin and midazolam.

Cathrine Denton, PhD

Cathrine is developing a pharmacokinetic-pharmacodynamic model of the anti-parasitic agent and prodrug, pafuramidine, which is the only orally active agent that has shown efficacy in clinical trials for the treatment of African sleeping sickness. She also is conducting a clinical study to elucidate the importance of an alternate metabolic pathway of midazolam, a "gold standard" probe substrate for cytochrome P450 3A.

Kristina Wolf, PhD

Kristina is investigating intestinal metabolism- and transporter-based drug-fruit juice interactions involving cranberry juice and grapefruit juice utilizing both human intestine-derived in vitro systems and healthy volunteer studies. She also is validating analytical methods to elucidate the disposition of investigational anti-parasitic agents in rodent and primate models of African sleeping sickness.

Christina Won, PharmD

Christina is investigating pharmacokinetic mechanisms underlying food-drug interactions, specifically those involving inhibition of intestinal absorptive uptake transport proteins (organic anion transporting polypeptides; OATPs). Using grapefruit juice as a model food, she is utilizing an in vitro-in silico-in vivo approach to predict the likelihood and magnitude of interactions between grapefruit juice and clinically relevant intestinal OATP substrates, including fexofenadine, fluoroquinolones, and beta-blockers.